Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): A randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX

Annals of Oncology

Volumn 27, Issue 6, 2016, Pages 1055-1061

  Ciardiello, F ^a   Normanno, N ^b   Martinelli, E ^a   Troiani, T ^a   Pisconti, S ^c   Cardone, C ^a   Nappi, A ^a   Bordonaro, A R ^d   Rachiglio, M ^b   Lambiase, M ^b   Latiano, T P ^e   Modoni, G ^c   Cordio, S ^d   Giuliani, F ^f   Biglietto, M ^g   Montesarchio, V ^h   Barone, C ⁱ   Tonini, G ^j   Cinieri, S ^k   Febbraro, A ^l   Rizzi, D ^m   Vita, F De ^a   Orditura, M ^a   Colucci, G ^f   Maiello, E ^e   Iaffaioli, Vincenzo ^b   Nasti, Guglielmo ^b   Botti, Gerardo ^b   Tatangelo, F ^b   Chicchinelli, Nicoletta ^b   Montrone, Mirko ⁿ   Sebastio, Annamaria ⁿ   Guarino, Tiziana ⁿ   Simone, Gianni ^f   Graziano, Paolo ^e   Chiarazzo, Cinzia ^e   Maggio, Gabriele Di ^e   Longhitano, Laura ^o   Manusia, Mario ^o   Cartenì, Giacomo ^g   Nappi, Oscar ^g   Micheli, Pietro ^h   Leo, Luigi ^h   Rossi, Sabrina ⁱ   Cassano, Alessandra ⁱ   Tommaselli, Eugenio ^p   Giordano, Guido ^p   Sponziello, Francesco ^q   Marino, Antonella ^q   Rinaldi, Antonio ^r   Romito, Sante ^s   Muda, Andrea Onetti ^j   Lorusso, Vito ^t   Leo, Silvana ^t   Barni, Sandro ^u   Grimaldi, Giuseppe ^v   Aieta, Michele ^w   more..

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c SS Annunziata Hospital   (Italy)

^d Garibaldi Central Hospital   (Italy)

^e CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^f NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^g CARDARELLI HOSPITAL   (Italy)

^h MONALDI HOSPITAL   (Italy)

ⁱ FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^j University Hospital A Gemelli ^*  (Italy)

^k A Perrino Hospital   (Italy)

^l Department of Radiology   (Italy)

^m GOIM Trial Office   (Italy)

ⁿ Stabilimento SS   (Italy)

^o GARIBALDI HOSPITAL   (Italy)

^p UO of Dermatology   (Italy)

^q Unit of Dermatology   (Italy)

^r Presidio Ospedaliero Polo Occidentale   (Italy)

^s Ospedali Riuniti di Foggia   (Italy)

^t VITO FAZZI HOSPITAL   (Italy)

^u Medical Oncology   (Italy)

^v Ospedale Umberto I   (Italy)

^w REFERRAL CANCER CENTER OF BASILICATA   (Italy)

more..

Author keywords

Cetuximab; Colorectal cancer; FOLFOX; NGS

Indexed keywords

B RAF KINASE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PIK3CA PROTEIN, HUMAN; PLATINUM COMPLEX; PROTEIN P21;

ADULT; AGED; ARTICLE; BRAF GENE; CONTROLLED STUDY; DRUG EFFICACY; DRUG WITHDRAWAL; EXON; FEMALE; HUMAN; HUMAN TISSUE; ITALY; KRAS GENE; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; NEXT GENERATION SEQUENCING; NRAS GENE; ONCOGENE; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PIK3CA GENE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; GENETICS; METASTASIS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CETUXIMAB; CLASS I PHOSPHATIDYLINOSITOL 3-KINASES; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; ITALY; LEUCOVORIN; MALE; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS); TREATMENT OUTCOME;

EID: 84974792739     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw136     Document Type: Article

References (21)

1. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008; 358: 1160-1174.
2. Van Cutsem E, Lenz HJ, Köhne CH et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in cancer. J Clin Oncol 2015; 33: 692-700.
3. Douillard JY, Oliner KS, Siena S et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013; 369: 1023-1034.
4. Heinemann V, von Weikersthal LF, Decker T et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15: 1065-1075.
5. De Roock W, De Vriendt V, Nomanno N et al. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 2011; 12: 594-603.
6. Ciardiello F, Normanno N, Maiello E et al. Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial. Ann Oncol 2014; 25: 1756-1761.
7. Normanno N, Rachiglio AM, Lambiase M et al. Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial. Ann Oncol 2015; 26: 1710-1714.
8. Bennouna J, Sastre J, Arnold D et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013; 14: 29-37.
9. Van Cutsem E, Tabernero J, Lakomy R et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatinbased regimen. J Clin Oncol 2012; 30: 3499-3506.
10. Tabernero J, Yoshino T, Cohn AL et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 2015; 16: 499-508.
11. Baselga J. Treatment of HER2-overexpressing breast cancer. Ann Oncol 2010; 21 (Suppl 7): vii36-vii40.
12. Bokemeyer C, Köhne CH, Ciardiello F et al. FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. Eur J Cancer 2015; 51: 1243-1252.
13. Misale S, Di Nicolantonio F, Sartore-Bianchi A, Siena S, Bardelli A. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov 2014; 4: 1269-1280.
14. Bertotti A, Migliardi G, Galimi F et al. A molecularly annotated platform of patientderived xenografts ('xenopatients') identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov 2011; 1: 508-523.
15. Bardelli A, Corso S, Bertotti A et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov 2013; 3: 658-673.
16. Troiani T, Martinelli E, Napolitano S et al. Increased TGF-a as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells. Clin Cancer Res 2013; 19: 6751-6765.
17. Ciardiello F, Normanno N. HER2 signaling and resistance to the anti-EGFR monoclonal antibody cetuximab: a further step toward personalized medicine for patients with colorectal cancer. Cancer Discov 2011; 6: 472-474.
18. Montagut C, Dalmases A, Bellosillo B et al. Identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer. Nat Med 2012; 22: 221-223.
19. Esposito C, Rachiglio AM, La Porta ML et al. The S492R EGFR ectodomani mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies. Cancer Biol Ther. 2013; 14(12): 1143-1146.
20. Bettegowda C, Sausen M, Leary RJ et al. Detection of circulating tumor DNA in early- and late-stage malignancies. Sci Transl Med 2014; 6(224): 224-248.
21. Morelli MP, Overman MJ, Dasari A et al. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann Oncol 2015; 26(4): 731-736.